Angeli A - Search Results

1

Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.

Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O. Fusco V, et al. Among authors: angeli a. J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4. doi: 10.1200/JCO.2011.35.1551. Epub 2011 May 2. J Clin Oncol. 2011. PMID: 21537047 No abstract available.

2

Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Berruti A, Tucci M, Terrone C, Scarpa RM, Angeli A, Dogliotti L. Berruti A, et al. Among authors: angeli a. J Natl Cancer Inst. 2003 Feb 19;95(4):332-3; author reply 333-4. doi: 10.1093/jnci/95.4.332-b. J Natl Cancer Inst. 2003. PMID: 12591993 Clinical Trial. No abstract available.

3

Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.

Berruti A, Tucci M, Mosca A, Vana F, Ardine M, Dogliotti L, Angeli A, Bertoldo F. Berruti A, et al. Among authors: angeli a. J Clin Oncol. 2007 Apr 10;25(11):1455-6. doi: 10.1200/JCO.2006.08.7080. J Clin Oncol. 2007. PMID: 17416873 No abstract available.

4

Hyperparathyroidism due to the so-called bone hunger syndrome in prostate cancer patients.

Berruti A, Dogliotti L, Tucci M, Scarpa RM, Angeli A. Berruti A, et al. Among authors: angeli a. J Clin Endocrinol Metab. 2002 Apr;87(4):1910-1; author reply 1911. doi: 10.1210/jcem.87.4.8423. J Clin Endocrinol Metab. 2002. PMID: 11932346 No abstract available.

5

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma.

Berruti A, Tucci M, Dogliotti L, Scarpa RM, Angeli A. Berruti A, et al. Among authors: angeli a. Cancer. 2002 Sep 1;95(5):1182-3; author reply 1183-4. doi: 10.1002/cncr.10770. Cancer. 2002. PMID: 12209706 Free article. No abstract available.

6

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L. Berruti A, et al. Among authors: angeli a. Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002. Drugs Aging. 2002. PMID: 12495366 Review.

7

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.

Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Generali D, et al. Among authors: angeli a. Br J Cancer. 2008 Jun 3;98(11):1753-8. doi: 10.1038/sj.bjc.6604390. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506177 Free PMC article. Clinical Trial.

8

Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment.

Berruti A, Dogliotti L, Osella G, Cerutti S, Reimondo G, Martino A, Gorzegno G, Catolla R, Angeli A. Berruti A, et al. Among authors: angeli a. Oncol Rep. 2000 Jul-Aug;7(4):777-81. doi: 10.3892/or.7.4.777. Oncol Rep. 2000. PMID: 10854543 Clinical Trial.

9

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.

Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A. Orlandi F, et al. Among authors: angeli a. Ann Oncol. 1994 Oct;5(8):763-5. doi: 10.1093/oxfordjournals.annonc.a058984. Ann Oncol. 1994. PMID: 7826911 Free article. Clinical Trial.

10

Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.

Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Berruti A, et al. Among authors: angeli a. J Urol. 2001 Dec;166(6):2023-31. J Urol. 2001. PMID: 11696699 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

729 results

Search Page